Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 421-434, September 2006

Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas

  • Pierre-François Plouin (Professor of Vascular Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +33 1 56 09 37 73; Fax: +33 1 56 09 37 91.

Hypertension Unit, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris; Université René Descartes-Paris 5; INSERM U772, Collège de France, Paris, France; and the COMETE (COrtico and MEdullo-surrenale: les Tumeurs Endocrines) and ENS@T (European Network for the Study of Adrenal Tumors) networks

Department of Genetics, Hôpital Européen Georges Pompidou, Paris, France

COMETE and PGL.NET networks

Catecholamine-producing tumours may arise in the adrenal medulla (phaeochromocytomas) or in extra-adrenal chromaffin cells (paragangliomas). The most specific and sensitive diagnostic test is the determination of plasma or urinary metanephrine levels. The tumour can be located by computed tomography, magnetic resonance imaging and metaiodo-benzylguanidine scintigraphy. Patients are treated by tumour resection. Phaeochromocytomas and paragangliomas may be sporadic or the result of several genetic diseases: multiple endocrine neoplasia type 2, neurofibromatosis 1, von Hippel-Lindau disease, succinate dehydrogenase–phaeochromocytoma–paraganglioma syndrome. Familial cases are diagnosed earlier and are more frequently bilateral and recurrent than sporadic cases. About 10% of tumours are malignant, either at initial surgery or during follow-up. Recurrences and malignancy are more frequent in cases with large or extra-adrenal tumours and in the succinate dehydrogenase subunit B-related phaeochromocytoma–paraganglioma syndrome. Patients should be followed up indefinitely, particularly if they have familial or extra-adrenal tumours.

Key words: catecholamines, hereditary disease, metanephrine, neoplasm, malignant, paraganglioma, phaeochromocytoma, recurrence

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-690X(06)00050-9

doi:10.1016/j.beem.2006.07.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 421-434, September 2006